1. G-CSF treatment in decompensated liver disease: a double-edged sword?

   • Cornelius Engelmann
   • Thomas Berg

   Editorial Open access 02 September 2022 Pages: 979 - 982

2. Management of spontaneous portosystemic shunts at the time of liver transplantation: treatment or observation? Results of a systematic review

   • Caterina Cusumano
   • Stefano Gussago
   • Pietro Addeo

   Review Article 08 August 2022 Pages: 983 - 992

   

3. Liver transplantation in patients with acute-on-chronic liver failure

   • Gandhi Lanke
   • Joseph J. Alukal
   • Paul J. Thuluvath

   Review Article 29 July 2022 Pages: 993 - 1000

   

4. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5

   • Chen-Hua Liu
   • Jia-Horng Kao

   Review Article 25 July 2022 Pages: 1001 - 1019

5. Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review

   • Jonathan Li
   • Vivian Wu
   • Calvin Q. Pan

   Review Article 09 September 2022 Pages: 1020 - 1031

   

6. MAFLD, patient-centred care, and APASL

   • Shiv K. Sarin
   • Mohammed Eslam
   • Masao Omata

   Point-of-View 07 September 2022 Pages: 1032 - 1034

7. Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study

   • Aruhan Yang
   • Xiaoxue Zhu
   • Guoyue Lv

   Original Article 12 July 2022 Pages: 1035 - 1051

   

8. Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease

   • Yuanyuan Kong
   • Tingting Lv
   • the BAVENO Cooperation: an EASL consortium

   Original Article 09 September 2022 Pages: 1052 - 1063

   

9. The regulation effect of GLUT9/SLC2A9 on intrahepatic uric acid level and metabolic associated fatty liver disease

   • Hang Zeng
   • Chenxi Tang
   • Chaohui Yu

   Original Article 25 August 2022 Pages: 1064 - 1074

   

10. CT-based visual grading system for assessment of hepatic steatosis: diagnostic performance and interobserver agreement

    • Hyo Jung Park
    • Kyoung Won Kim
    • Sung-Gyu Lee

    Original Article 05 July 2022 Pages: 1075 - 1084

    

11. Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male

    • Xiao-Yan Pan
    • Wen-Yue Liu
    • Ming-Hua Zheng

    Original Article 13 July 2022 Pages: 1085 - 1093

    

12. Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study

    • Natassia Tan
    • N. Ngu
    • the Melbourne Liver Group

    Original Article Open access 03 June 2022 Pages: 1094 - 1104

    

13. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study

    • Chuan Liu
    • Jia Li
    • Xiaolong Qi

    Original Article 24 May 2022 Pages: 1105 - 1115

    

14. Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure

    • Xiuying Mu
    • Jun Zou
    • Fu-Sheng Wang

    Original Article 28 February 2022 Pages: 1116 - 1126

    

15. Multiple cycles of granulocyte colony-stimulating factor in decompensated cirrhosis: a double-blind RCT

    • Aswath Venkitaraman
    • Arka De
    • Virendra Singh

    Original Article 23 March 2022 Pages: 1127 - 1136

    

16. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma

    • Nai-Jung Chiang
    • Ya-Chin Hou
    • Yan-Shen Shan

    Original Article 03 July 2022 Pages: 1137 - 1149

    

17. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

    • Takeshi Hatanaka
    • Satoru Kakizaki
    • On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

    Original Article 24 June 2022 Pages: 1150 - 1160

    

18. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain

    • José-Manuel Ramos-Rincon
    • Héctor Pinargote-Celorio
    • Vicente Soriano

    Original Article 06 June 2022 Pages: 1161 - 1169

    

19. Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study

    • Kurvi Patwala
    • David Stephen Prince
    • Anouk Dev

    Original Article Open access 25 August 2022 Pages: 1170 - 1178

    

20. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial

    • Jian-Xu Li
    • Ting-Shi Su
    • Bang-De Xiang

    Original Article Open access 24 August 2022 Pages: 1179 - 1187

    

21. A deep learning model with incorporation of microvascular invasion area as a factor in predicting prognosis of hepatocellular carcinoma after R0 hepatectomy

    • Kang Wang
    • Yanjun Xiang
    • Shuqun Cheng

    Original Article 24 August 2022 Pages: 1188 - 1198

    

22. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment

    • Ching-Tso Chen
    • Yin-Hsun Feng
    • Yu-Yun Shao

    Original Article 20 August 2022 Pages: 1199 - 1207

    

23. Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study

    • Ke Su
    • Yanlin Liu
    • Yunwei Han

    Original Article Open access 16 August 2022 Pages: 1208 - 1219

    

24. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma

    • Chuan Jin
    • Jian-Sen Zhao
    • Ye Song

    Original Article 10 August 2022 Pages: 1220 - 1233

    

25. Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)

    • Sanchit Sharma
    • Samagra Agarwal
    • APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party

    Original Article 18 July 2022 Pages: 1234 - 1243

    

26. Aspirin for patients after TIPS: an old dog with new tricks?

    • Jitao Wang
    • Dengxiang Liu
    • Xiaolong Qi

    Letter to the Editor 29 June 2022 Pages: 1244 - 1245

27. Response to: Aspirin for patients after TIPS. An old dog with new tricks?

    • Leon Louis Seifert
    • Philipp Schindler
    • Hauke Heinzow

    Letter to the Editor Open access 29 July 2022 Pages: 1246 - 1247

28. Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?

    • Xiaobing Wang
    • Liping Chen

    Letter to the Editor 18 August 2022 Pages: 1248 - 1249

29. Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues

    • Yitao Zheng
    • Xiaming Huang
    • Hongqi Shi

    Letter to the Editor 25 August 2022 Pages: 1250 - 1251